Cipla's inhaler Sereflo gets UK MHRA nod

Pharma firm Cipla's inhaler 'Sereflo', used for treatment of asthma, has received final approval from the UK Medicines and Healthcare products regulatory agency (UKMHRA).
The company's metered dose inhaler (MDI) product, Sereflo (Fluticasone and Salmeterol) has been given final approval by the UK MHRA, Cipla said in a filing to BSE.
Sereflo 25 mcg/125 mcg and 25 mcg/250 mcg are generic equivalent to GlaxoSmithKline's Seretide inhalers and are indicated for asthma treatment, it added.
"Seretide inhaler, for the aforementioned strengths, had the UK sales of approximately USD 278 million for the 12 month period ending June 2016, according to IMS Health," Cipla said.

The company's product will be launched in the UK through a partner in the coming weeks, it added.
Commenting on the development, Cipla MD and Global CEO Umang Vohra said : "This is a testament of Cipla's relentless efforts in the respiratory field for over a decade."
Shares of Cipla ended 3.74 per cent up at Rs 581.15 on BSE.